Navigation Links
Pharmasset Reports Fiscal Year End 2011 Financial Results
Date:11/14/2011

0;Screening and enrollment for this open-label study have progressed quickly, and interim results from the first half of the subjects enrolled are anticipated in the second calendar quarter of 2012.

MericitabineRoche is currently conducting a number of phase 2 studies with mericitabine, including the INFORM-SVR study in combination with ritonavir-boosted danoprevir with and without ribavirin for 12 or 24 weeks in patients with HCV GT1. Roche recently announced an additional arm added to INFORM-SVR to assess a 24 week regimen of mericitabine, boosted danoprevir and ribavirin in HCV genotype 1 patients contraindicated for or intolerant of interferon. In June 2011, Roche initiated a second trial, MATTERHORN, to evaluate ritonavir-boosted danoprevir and ribavirin in combination with mericitabine and/or pegylated interferon. The study is expected to enroll approximately 420 subjects with HCV GT1 who failed previous therapy. Roche has stated that it intends to file mericitabine for marketing approval in 2014.

Financial ResultsFor the fiscal year ended September 30, 2011 Pharmasset reported revenues of $0.9 million, compared with revenues of $1.0 million for fiscal year 2010. Revenues during each fiscal year primarily consist of amortization of up-front and subsequent collaborative and license payments received from Roche previously recorded as deferred revenue.  

Total costs and expenses for the fiscal year ended September 30, 2011 were $92.5 million compared to $64.7 million for the same period in 2010. The increase in operating expenses was primarily the result of increased clinical development costs associated with the initiation and ongoing conduct of the Phase 2 studies ELECTRON and ATOMIC, as well as the advancement of PSI-938 in NUCLEAR and the large Phase 2b study, QUANTUM.

Pharmasset reported a net loss of $91.2 million, or $1.25 per share for the fiscal year ended September 30, 2011, as compared to a net loss of $66
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
5. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
10. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
11. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Oct. 24, 2011 Marshall Edwards, Inc. (Nasdaq: ... of novel therapeutics targeting cancer metabolism, announced today that Charles ... Company, has been appointed to its board of directors. The ... to six and the number of independent directors to five. ...
... (NYSE symbol: OME), a nutritional ingredient company and the ... fish meal products, today announced that it has retained ... with its omega-3 fish oil and omega-3 concentrate research ... analytical services and biotechnology consulting company that specializes in ...
... Oct. 24, 2011 Heart repair.  Bone repair. ...  Cerebral Palsy.  Diabetes.  Alzheimer,s.  Cystic Fibrosis.  Leukemia, Sickle ... metabolic disorders. "These diseases or group ... cured with umbilical cord blood stem cells or ...
Cached Biology Technology:Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3Omega Protein Announces Retention of Lipid Technologies, LLC 2Cord Blood America Provides Insight on Worldwide Research Using Umbilical Cord Blood Stem Cells to Treat Numerous Diseases 2Cord Blood America Provides Insight on Worldwide Research Using Umbilical Cord Blood Stem Cells to Treat Numerous Diseases 3
(Date:4/22/2014)... club of a mantis shrimp, a team of researchers ... University of Southern California and Purdue University, have developed ... impact resistant and tougher than the standard used in ... this tiny crustacean, the more we realize its structure ... said David Kisailus, a Kavli Fellow of the National ...
(Date:4/22/2014)... Biology (FASEB) has released updated factsheets for ... National Institutes of Health (NIH) benefits each of the ... to make these factsheets available to help citizens and ... said FASEB President, Margaret K. Offermann, MD, PhD. NIH ... funding, investing $29.2 billion in FY 2013 in medical ...
(Date:4/22/2014)... begins a trip to Asia to coordinate with ... Pacific, officials at the Office of Naval Research ... Partnership (APTEP) as an example of strong and ... allies in the region. , The APTEP program, ... region, supports the development of alternative energy technologies. ...
Breaking Biology News(10 mins):Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3
... CREEK, CAMessages from nearly a half-billion years ago, conveyed ... moss, provide clues about the earliest colonization of dry ... Joint Genome Institute (DOE JGI) was among the leaders ... to complete the first genome sequencing project of a ...
... published a paper today that is the most comprehensive ... are having on the worlds coral reefs. The ... and Ocean Acidification, co-authored by seventeen marine scientists from ... not survive the drastic increases in global temperatures and ...
... The Stowers Institutes Rong Li Lab, in collaboration ... quantitative in vivo measurement of the dynamic protein-protein ... signaling pathway, which is critical to growth and ... paper, Mapping Dynamic Protein Interactions in the MAP ...
Cached Biology News:DOE JGI Community Sequencing Program delivers first moss genome 2DOE JGI Community Sequencing Program delivers first moss genome 3Immediate action needed to save corals from climate change 2Immediate action needed to save corals from climate change 3Rong Li Lab reports protein interactions of MAP kinase signaling pathway 2
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... The Jouan B4i ventilated and BR4i refrigerated multifunction ... low speed operation at a low sound level ... certified for biocontainment. Their AUTO-LOCK rotor exchange system ... ready for use within seconds. Instant ...
... BR4i refrigerated multifunction centrifuges are equally capable of ... low sound level with a large range of ... rotor exchange system without tools ensures that the ... Instant rotor exchange (5 sec.) ...
Biology Products: